Q2 2025 Management View CEO David L. Hallal emphasized Scholar Rock is “scaling for the next phase of growth as a commercial stage fully integrated global biopharmaceutical company.” He outlined three ...

August 6, 2025Scholar Rock Holding Corporation misses on earnings expectations. Reported EPS is $-0.98 EPS, expectations were $-0.66. Operator: Good morning, ladies and gentlemen, and welcome to the ...

No revenue was recorded as the company remains pre-commercial, in line with analyst expectations. R&D and G&A expenses surged 47% and 191% year over year as apitegromab advanced toward anticipated U.S ...

Shares of Scholar Rock (NASDAQ: SRRK) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate ...

Scholar Rock's stock is down 45% in the year through Friday's close, while the S&P 500 SPX has gained 20.6%. -Ciara Linnane ...

Shares of Scholar Rock Holding (NASDAQ: SRRK) are soaring today, up 13.7% as of 1:14 p.m. ET. The move comes as the S&P 500 and Nasdaq Composite were up modestly.

Scholar Rock's cash burn was increasing - net losses between 2020 and 2023 were $ (86.5m), $ (132m), $ (135m), and $ (166m), and its share price had declined to ~$6.5 by October 2023.

Scholar Rock Holding focuses on the discovery of drugs for treating illnesses, in which signaling by protein growth factors is important. SRRK tested a total of 58 patients in Phase 2.

Shares of Scholar Rock Holding Corp. (SRRK -3.46%) skyrocketed as much as 35% early Thursday, then settled to trade up 13.7% as of 3 p.m. ET after the company announced an expansion into ...

Scholar Rock’s newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal ...

Scholar Rock believes that SRK-181 has the potential to overcome this immunosuppressive tumor microenvironment and induce tumor regression when administered in combination with anti-PD- (L)1 ...

Scholar Rock announces a presentation of apitegromab TOPAZ Phase 2 clinical trial results at the 2021 Virtual SMA Research and Clinical Care Meeting.